Postbiotics are nonliving products from microbes that show promise as helpful compounds for treating various diseases, including colorectal cancer (CRC). They are created during the fermentation process in the gut and include substances such as short-chain fatty acids (SCFAs), peptides, and lipopolysaccharides. In CRC, postbiotics can help fight cancer by influencing important metabolic pathways that affect cancer growth. Short-chain fatty acids (SCFAs), like butyrate, propionate, and acetate, serve a vital function in controlling cell growth, programmed cell death, and inflammation, all of which are connected to colorectal cancer development. For instance, butyrate can trigger cancer cell death while supporting the growth of healthy colon cells. Moreover, postbiotics can affect gene expression and immune responses, making the body less likely to develop cancer. Additionally, postbiotics can impact major metabolic pathways like Wnt/β-catenin, PI3K/Akt, and mTOR, which are often disrupted in CRC. By targeting these pathways, postbiotics may slow down tumor growth and limit the spread of cancer. The relationship between postbiotics from gut bacteria and the body’s metabolic signals presents a new way to prevent and treat CRC. More studies on specific postbiotic compounds and how they work could lead to new strategies for managing colorectal cancer.